Pulmonale Hypertonie: Update 2019

ZUSAMMENFASSUNG

Pulmonale Hypertonie (PH) ist ein hämodynamischer Zustand, der als gemeinsame Konsequenz einer Reihe von Erkrankungen entstehen kann, die aufgrund unterschiedlicher Pathomechanismen zu einer Erhöhung des pulmonal arteriellen Drucks und infolge dessen zu chronischer Rechtsherzbelastung führen. Je nach zugrunde liegender Ursache untergliedert die klinische Klassifikation die PH in 5 Gruppen: Pulmonal arterielle Hypertonie (Gruppe 1), PH in Zusammenhang mit Linksherzerkrankungen (Gruppe 2), PH bei chronischen Lungenerkrankungen (Gruppe 3), chronisch-thromboembolische PH (CTEPH; Gruppe 4) und PH aufgrund unklarer und/oder multifaktorieller Mechanismen (Gruppe 5). Dieser Artikel fokussiert auf die klinische Relevanz dieser Untergliederung und das unterschiedliche Management der verschiedenen PH-Formen. Er beleuchtet zudem kritisch neue Entwicklungen wie die modifizierte hämodynamische Definition der PH.

• Literatur

• 1 Galiè N, Humbert M, Vachiery JL. et al 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67-119
• 2 Rosenkranz S, Gibbs SR J, Wachter R. et al Left ventricular heart failure and pulmonary hypertension. Eur Heart J 2016; 37: 942-954
• 3 Hoeper MM, Humbert M, Souza R. et al A global view of pulmonary hypertension. Lancet Respir Med 2016; 4: 306-322
• 4 Assad TR, Maron BA, Robbins IM. et al Prognostic effect and longitudinal hemodynamic assessment of borderline pulmonary hypertension. JAMA Cardiol 2017; 2: 1361-1368
• 5 Maron BA, Hess E, Maddox TM. et al Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: Insights from the Veterans Affairs clinical assessment, reporting, and tracking program. Circulation 2016; 133: 1240-1248
• 6 Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. Proceedings of the 6^th World Conference on Pulmonary Hypertension, Nice 2018. Eur Respir J 2019: 53 DOI: 10.1183/13993003.02148–2018
• 7 Rosenkranz S, Ghofrani HA, Grünig E. et al Cologne Consensus Conference on Pulmonary Hypertension – Update 2018. Int J Cardiol 2018; 272 S 1-3
• 8 Hoeper MM, Bogaard HJ, Condliffe R. et al Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D42-D50
• 9 Mc Laughlin VV, Archer SL, Badesch DB. et al ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619
• 10 Simmoneau G, Montani D, Celermayer DS. et al Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019: 53 DOI: 10.1183/13993003.01913–2018
• 11 Rosenkranz S, Diller GP, Dumitrescu D. et al Hämodynamische Definition der pulmonalen Hypertonie: Kommentar zu der vorgeschlagenen Änderung durch das 6^th World Symposium on Pulmonary Hypertension. Dtsch Med Wochenschr 2019 DOI: 10.1055/a-0918-3772
• 12 Kovacs G, Berghold A, Scheidl S. et al Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34: 888-894
• 13 Douschan P, Kovacs G, Avian A. et al Mild elevation of pulmonary arterial pressure as a predictor of mortality. Am J Respir Crit Care Med 2018; 197: 509-516
• 14 Kolte D, Lakshmanan S, Jankowich MD. et al Mild pulmonary hypertension is associated with increased mortality: A systematic review and meta-analysis. J Am Heart Assoc 2018; 7: e009729
• 15 Galiè N, Channick R, Frantz RP. et al Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019: 53 doi: 10.1183/13993003.01889-2018
• 16 Hoeper MM, Apitz C, Grünig E. et al Targeted therapy of pulmonary arterial hypertension: Updated recommendations of the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272 S 37-45
• 17 McLaughlin VV, Hoeper MM, Channick RN. et al Pulmonary arterial hypertension-related morbidity is prognostic for mortality. J Am Coll Cardiol 2018; 71: 752-763
• 18 Grünig E, Benjamin N, Krüger U. et al General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018: 272S 30-36
• 19 Vachiéry JL, Tedford RJ, Rosenkranz S. et al Pulmonary hypertension due to left heart disease. Eur Respir J 2019: 53 doi: 10.1183/13993003.01897-2018
• 20 Rosenkranz S, Lang IM, Blind R. et al Pulmonary hypertension associated with left heart disease: Updated recommendations of the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272 S 53-62
• 21 Guazzi M, Naeije R. Pulmonary hypertension in heart failure: Pathophysiology, pathobiology, and emerging clinical perspectives. J Am Coll Cardiol 2017; 69: 1718-1734
• 22 Vanderpool RR, Saul M, Nouraie M, Gladwin MT, Simon MA. Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol 2018; 3: 298-306
• 23 Abraham WT, Stevenson LW, Bourge RC. et al for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 2016; 387: 453-461
• 24 Shavelle D, Akshay S, Desai MD. et al Pulmonary artery pressure-guided therapy for ambulatory heart failure patients in clinical practice: 1-year outcomes from the CardioMEMS post-approval study. J Am Coll Cardiol 2019 (Abstract presentation at ACC 2019)
• 25 Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011; 124: 164-174
• 26 Kramer T, Dumitrescu D, Gerhardt F, Orlova K, ten Freyhaus H, Hellmich M, Baldus S, Rosenkranz S. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. Int J Cardiol 2019; 283: 152-158
• 27 Nathan SD, Barbera JA, Gaine SP. et al Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019: 53 doi: 10.1183/13993003.01914-2018
• 28 Olschewski H, Behr J, Bremer H. et al Pulmonary hypertension due to lung diseases: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272 S 63-68
• 29 Boerrigter BG, Bogaard HJ, Trip P. et al Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 2012; 142: 1166-1174
• 30 Mahmut E, Madani MM, Kim NH. et al Chronic thromboembolic pulmonary hypertension – Evolving therapeutic approaches for operable and inoperable disease. J Am Coll Cardiol 2018; 71: 2468-2486
• 31 Delcroix M, Staehler G, Gall H, Grünig E, Held M, Halank M, Klose H, Vonk-Noordegraaf A, Rosenkranz S, Pepke-Zaba J, Opitz CF, Gibbs JSR, Lange TJ, Tsagkaris I, Huscher D, David Pittrow D, Hoeper MM. Risk assessment in chronic thromboembolic pulmonary hypertension. Eur Respir J 2018: 52 pii: 1800248
• 32 Kim NH, Delcroix M, Jais X. et al Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019: 53 doi: 10.1183/13993003.01915-2018
• 33 Wilkens H, Konstantinides S, Lang I. et al Chronic thromboembolic pulmonary hypertension (CTEPH): Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272 S 69-78